Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial

Mainz, J.G.; Mentzel, Heribert; Schneider, G; Riethmüller, Joachim; Schiller, Irving W.; Ritschel, Christiane; Beck, Jürgen; Wiedemann, Bärbel

doi:10.1016/s1569-1993(08)60104-6

Cited by 18 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a previous study, we showed the efficiency of Kr-gas ventilation and aerosolized drug delivery to the paranasal sinuses in a nasal cast model using pulsating airflows 9 . This hypothesis is further supported by clinical data on nasal administration of dornase alpha (Pulmozyme, Roche Pharma AG, Grenzach-Wyhlen, Germany) via pulsating aerosol delivery (PARI SINUS, PARI Pharma GmbH, Starnberg, Germany) in cystic fibrosis patients 10 …”

mentioning

confidence: 56%

Pulsating aerosols for drug delivery to the sinuses in healthy volunteers

Möller

Schuschnig

Saba

et al. 2010

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 56%

Pulsating aerosols for drug delivery to the sinuses in healthy volunteers

Möller

Schuschnig

Saba

et al. 2010

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…Efficacy has been demonstrated for saline irrigation, and irrigation with anti-pseudomonal antibiotics in colonised patients with CF and PCD has also been used as an adjunct to sinus surgery [139,140]. In CF, nasal irrigation with recombinant human DNAse has resulted in improvements in nasal symptom score and lung function [141][142][143]. Recently, sinonasal surgery has been shown to improve bronchiectasis symptoms and decrease the frequency of exacerbations [144].…”

Section: Upper Airway Involvement In Bronchiectasismentioning

confidence: 99%

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions

et al. 2018

View full text Add to dashboard Cite

Bronchiectasis is a clinical and radiological diagnosis associated with cough, sputum production and recurrent respiratory infections. The clinical presentation inevitably overlaps with other respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). In addition, 4-72% of patients with severe COPD are found to have radiological bronchiectasis on computed tomography, with similar frequencies (20-30%) now being reported in cohorts with severe or uncontrolled asthma. Co-diagnosis of bronchiectasis with another airway disease is associated with increased lung inflammation, frequent exacerbations, worse lung function and higher mortality. In addition, many patients with all three disorders have chronic rhinosinusitis and upper airway disease, resulting in a complex "mixed airway" phenotype.The management of asthma, bronchiectasis, COPD and upper airway diseases has traditionally been outlined in separate guidelines for each individual disorder. Recognition that the majority of patients have one or more overlapping pathologies requires that we re-evaluate how we treat airway disease. The concept of treatable traits promotes a holistic, pathophysiology-based approach to treatment rather than a syndromic approach and may be more appropriate for patients with overlapping features.Here, we review the current clinical definition, diagnosis, management and future directions for the overlap between bronchiectasis and other airway diseases.

show abstract

“…This was initially found to be beneficial for pulmonary function, namely a decrease in decline of lung function in patients with CF [25]. A recent double-blind placebo controlled cross-over trial by Mainz et al [26] evaluated the effects of dornase alpha when administered in the early postoperative period. A significant improvement in sinonasal outcome test (SNOT-20) scores was seen when compared with administration of isotonic nasal saline irrigation.…”

Section: Dornase Alphamentioning

confidence: 99%